Follow The Filings

ENTA Enanta Pharmaceuticals Inc.

Health Care, filed as ENANTA PHARMACEUTICALS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q3

  • 3 Owners
  • Max 14.2%
  • $52M
  • 1 reduce

In 2026 Q3 Farallon Capital Management trimmed Enanta Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 14.2% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage 14.2%
  2. James Silverman 0.19%
  3. Farallon Capital Management Reduce 0.05%

Who owns ENTA

Sorted by value, long equity only, as of 2026 Q3.

History
Michael Krensavage, Krensavage Asset Management 14.2% Hold 2,866,138 $38M History
Farallon Capital Management 0.05%, was 0.16% Reduce −60.7% 950,000 $13M History
James Silverman, Opaleye Management 0.19% Hold 125,000 $1.6M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ENTA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ENTA insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 13 share withholdings for taxes, and 9 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
10-K
SCHEDULE 13G —
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 8.01
8-K 5.02,7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
424B5
8-K 1.01,9.01
8-K 8.01
8-K 7.01,9.01
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 8.01
8-K 5.02,5.07,9.01
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
DEF 14A

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue $79.2M $67.64M $65.32M $63M
Net income -$133.82M -$116.04M -$81.89M -$68.25M
Net margin * -169.0% -171.6% -125.4% -108.3%

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $422.79M $299.85M $204.34M $205.99M
Total non-current assets * $39.48M $76.8M $76.4M $69.58M
Total assets $462.28M $376.65M $280.73M $275.58M
Total current liabilities $62.79M $57.54M $48.56M $54.46M
Total non-current liabilities * $182.75M $190.3M $167.46M $140.92M
Total equity $216.74M $128.81M $64.72M $80.2M

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations -$103.15M -$78.76M -$19.27M -$42.56M
Cash from investing -$53.58M $58.24M $40.35M -$17.18M
Cash from financing $198.13M -$27.63M -$26.62M $47.72M
Net change in cash $41.39M -$48.16M -$5.54M -$12.03M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf